Highlights
- The ADVENT-AML trial of CHM CORE-NK progresses to the next cohort with approval from the safety monitoring committee.
- The second cohort will evaluate a higher dose of CHM CORE-NK in patients with AML.
- The trial is currently open for enrollment at The University of Texas MD Anderson Cancer Center.
Chimeric Therapeutics Limited (ASX: CHM) has announced a significant advancement in its Phase 1B ADVENT-AML trial, which is moving forward to the next cohort.
Data source: Company update
In the upcoming cohort, three patients with refractory or relapsed AML will receive CHM CORE-NK at dose level 2 in combination with venetoclax and azacitidine.
More about the ADVENT-AML Phase 1B trial
The ADVENT-AML Phase 1B trial is an investigator-initiated study.
Data source: Company update
Enrollment for the first cohort began in the first quarter of 2024. Three patients with refractory or relapsed AML were administered CHM CORE-NK at dose level 1 along with standard-of-care aza/ven. During the 28-day dose-limiting toxicities (DLT) assessment period, no DLTs were reported.
Following a thorough review of the data from these three patients, the safety monitoring committee authorised the trial to proceed to the next cohort.
CHM shares were trading at AU$0.017 apiece at the time of writing on 5 June 2024.